Phycocyanin prevents hypertension and low serum adiponectin level in a rat model of metabolic syndrome

Nutrition Research

Volumn 33, Issue 5, 2013, Pages 397-405

  Ichimura, Mayuko ^a   Kato, Shigeko ^a   Tsuneyama, Koichi ^b   Matsutake, Sachiko ^a   Kamogawa, Mai ^a   Hirao, Eri ^a   Miyata, Ayako ^a   Mori, Sawako ^a   Yamaguchi, Noriaki ^a   Suruga, Kazuhito ^a   Omagari, Katsuhisa ^a  

^a UNIVERSITY OF NAGASAKI   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Adiponectin; Endothelial nitric oxide synthase; Hypertension; Metabolic syndrome; Phycocyanin; SHR NDmcr cp rats

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR; CCAAT ENHANCER BINDING PROTEIN ALPHA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MESSENGER RNA; PHYCOCYANIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTERY ENDOTHELIUM; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; LOW DRUG DOSE; MALE; METABOLIC SYNDROME X; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPIRULINA; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA; BLOOD PRESSURE; BODY WEIGHT; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CYANOBACTERIA; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ENERGY INTAKE; HYPERTENSION; LIVER; MALE; METABOLIC SYNDROME X; NITRIC OXIDE SYNTHASE TYPE III; ORGAN SIZE; PHYCOCYANIN; RATS; RATS, INBRED SHR; RECEPTORS, ADIPONECTIN;

CHLOROPHYTA; RATTUS; SPIRULINA;

EID: 84878142968     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2013.03.006     Document Type: Article

References (28)

1. Bruce K.D., Hanson M.A. The developmental origins, mechanisms, and implications of metabolic syndrome. J Nutr 2010, 140:648-652.
2. Hajer G.R., van Haeften T.W., Visseren F.L.J. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008, 29:2959-2971.
3. Ritchie S.A., Ewart M.-A., Perry C.G., Connell J.M.C., Salt I.P. The role of insulin and the adipocytokines in regulation of vascular endothelial function. Clin Sci 2004, 107:519-532.
4. Calles-Escandon J., Cipolla M. Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
5. Hayashi O., Katoh T., Okuwaki Y. Enhancement of antibody production in mice by dietary Spirulina platensis. J Nutr Sci Vitaminol 1994, 40:431-441.
6. Torres-Duran P.V., Ferreira-Hermosillo A., Juarez-Oropeza M.A. Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report. Lipids Health Dis 2007, 6:33.
7. Fujimoto M., Tsuneyama K., Fujimoto T., Selmi C., Gershwin M.E., Shimada Y. Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis 2012, 44:767-774.
8. Eriksen N.T. Production of phycocyanin-a pigment with applications in biology, biotechnology, foods and medicine. Appl Microbiol Biotechnol 2008, 80:1-14.
9. Hirata T., Tanaka M., Ooike M., Tsunomura T., Sakaguchi M. Antioxidant activities of phycocyanobilin prepared from Spirulina platensis. J Appl Psychol 2000, 12:435-439.
10. Romay C., Armesto J., Remirez D., Gonzalez R., Ledon N., Garcia I. Antioxidant and anti-inflammatory properties of C-phycocyanin from blue-green algae. Inflamm Res 1998, 47:36-41.
11. Chiu H.-F., Yang S.-P., Kuo Y.-L., Lai Y.-S., Chou T.-C. Mechanisms involved in the antiplatelet effect of C-phycocyanin. Br J Nutr 2006, 95:435-440.
12. Ou Y., Zheng S., Lin L., Jiang Q., Yang X. Protective effect of C-phycocyanin against carbon tetrachloride-induced hepatocyte damage in vitro and in vivo. Chem Biol Interact 2010, 185:94-100.
13. Nagaoka S., Shimizu K., Kaneko H., Shibayama F., Morikawa K., Kanamaru Y., Otsuka A., Hirahashi T., Kato T. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina platensis concentrate in rats. J Nutr 2005, 135:2425-2430.
14. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.-C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
15. Nangaku M., Izuhara Y., Usuda N., Inagi R., Shibata T., Sugiyama S., Kurokawa K., van Ypersele de Strihou C., Miyata T. In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. Nephrol Dial Transplant 2005, 20:2661-2669.
16. Yamaguchi Y., Yoshikawa N., Kagota S., Nakamura K., Haginaka J., Kunitomo M. Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. Nitric Oxide 2006, 15:380-386.
17. Takai S., Jin D., Miyazaki M. Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ. J Pharmacol Sci 2011, 116:309-315.
18. Omagari K., Kato S., Tsuneyama K., Hatta H., Sato M., Hamasaki M., Sadakane Y., Tashiro T., Fukuhata M., Miyata Y., Tamaru S., Tanaka K., Mune M. Olive leaf extract prevents spontaneous occurrence of non-alcoholic steatohepatitis in SHR/NDmcr-cp rats. Pathology 2010, 42:66-72.
19. Kato S., Omagari K., Tsuneyama K., Fukazawa E., Tsukuda H., Inohara C., Kuroda Y., Shiraishi K., Mune M. A possible rat model for non-alcoholic steatohepatitis: histological findings in SHR/NDmcr-cp rats. Hepatol Res 2008, 38:743-744.
20. Kagota S., Tada Y., Nejime N., Nakamura K., Kunitomo M., Shinozuka K. Chronic production of peroxynitrite in the vascular wall impairs vasorelaxation function in SHR/NDmcr-cp rats, an animal model of metabolic syndrome. J Pharmacol Sci 2009, 109:556-564.
21. Uno K., Yamada T., Ishigaki Y., Imai J., Hasegawa Y., Gao J., Kaneko K., Matsusue K., Yamazaki T., Oka Y., Katagiri H. Hepatic peroxisome proliferator-activated receptor-γ-fat-specific protein 27 pathway contributes to obesity-related hypertension via afferent vagal signals. Eur Heart J 2012, 33:1279-1289.
22. Yanai H., Tomono Y., Ito K., Furutani N., Yoshida H., Tada N. The underlying mechanisms for development of hypertension in the metabolic syndrome. Nutr J 2008, 7:10.
23. Versari D., Daghini E., Virdis A., Ghiadoni L., Taddei S. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009, 157:527-536.
24. Rossi R., Chiurlia E., Nuzzo A., Cioni E., Origliani G., Modena M.G. Flow-mediated vasodilation and the risk of developing hypertension in healthy postmenopausal women. J Am Coll Cardiol 2004, 44:1636-1640.
25. Chiara T.D., Argano C., Corrao S., Scaglione R., Licata G. Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome. J Nutr Metab 2012, Article ID 175245. 10.1155/2012/175245.
26. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
27. Whitehead J.P., Richards A.A., Hickman I.J., Macdonald G.A., Prins J.B. Adiponectin-a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006, 8:264-280.
28. Chou T.-C., Yen M.-H., Li C.-Y., Ding Y.-A. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension 1998, 31:643-648.